Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to...

Area of Science:

• Immunology
• Hepatology
• Pharmacology

Background:

• Non-alcoholic steatohepatitis (NASH) involves systemic inflammation and fibrogenesis, making the immune system a key drug development target.
• The gut immune system is recognized for its role in generating signals that influence systemic immunity.

Purpose of the Study:

• To review seven emerging methods for treating NASH by targeting the gut immune system.
• To alleviate the systemic inflammatory response associated with NASH through gut-directed therapies.

Main Methods:

• A literature search was conducted for novel oral immunotherapy methods for NASH.
• The review focused on specific compounds including fatty-liver-derived proteins, anti-CD3 antibodies, TNF fusion protein, anti-LPS antibodies, glucosylceramide, mercaptopurine, and soy extracts.

Main Results:

• Oral administration allows immune modulation without general immune suppression, offering a safety advantage.
• These therapies target a broad spectrum of NASH pathology and can act as adjuncts for conditions like diabetes and hyperlipidaemia.
• Most reviewed compounds are in Phase II trials, indicating significant clinical development.

Conclusions:

• Oral immunotherapy presents a novel therapeutic platform for NASH.
• These gut-targeted approaches offer a potentially safer and more comprehensive treatment strategy for NASH patients.